Xtant Medical (NYSEAM:XTNT) Q4 2025 Earnings call March 31, 2026 08:30 AM ET Company ParticipantsKevin Gardner - Managing DirectorScott Neils - CFOSean Browne - President and CEOConference Call ParticipantsChase Knickerbocker - Senior Research AnalystNone - AnalystOperatorMorning everyone, and welcome to the Xtant Medical fourth quarter and full year 2025 financial results. At this time, all participants are in a listen-only mode, and the floor will be open for questions and comments following the presentat ...

Xtant Medical (NYSEAM:XTNT) Q4 2025 Earnings call March 31, 2026 08:30 AM ET Company ParticipantsKevin Gardner - Managing DirectorScott Neils - CFOSean Browne - President and CEOConference Call ParticipantsChase Knickerbocker - Senior Research AnalystNone - AnalystOperatorMorning everyone, and welcome to the Xtant Medical fourth quarter and full year 2025 financial results. At this time, all participants are in a listen-only mode, and the floor will be open for questions and comments following the presentat ...

Xtant Medical (NYSEAM:XTNT) Q4 2025 Earnings call March 31, 2026 08:30 AM ET Speaker2Morning everyone, and welcome to the Xtant Medical fourth quarter and full year 2025 financial results. At this time, all participants are in a listen-only mode, and the floor will be open for questions and comments following the presentation. Please note that this conference is being recorded. I will now turn the conference over to your host, Kevin Gardner of LifeSci Advisors. Kevin, please go ahead.Speaker1Thank you, oper ...

Summary of Xtant Medical Holdings Inc. Conference Call Company Overview - **Company**: Xtant Medical Holdings Inc. - **Industry**: Regenerative biologics and spinal implant systems - **Market Size**: The orthobiologics market is valued at $2.5 billion, with adjacent markets exceeding $10 billion [2][3] Core Points and Arguments - **Financial Performance**: The company has doubled in size since 2022, achieving record revenue, earnings, EBITDA, and positive cash flow in the last quarter [3][21] - **Balance Sheet Improvement**: The sale of non-core businesses will enhance focus on core operations and improve the balance sheet, with $19.2 million expected from the sale [5][20] - **Vertical Integration**: The company has achieved vertical integration, controlling product quality, supply chain, and margins, which enhances profitability [4][10][11] - **Product Development**: Xtant Medical is focused on developing best-in-class orthobiologics and expanding its product pipeline, including new offerings like SimplyMax, SimplyGraph, and OsteoVive Plus [13][15][17] - **Market Diversification**: The company is diversifying its revenue sources, reducing reliance on the spine market from over 90% to around 70% [9][18] - **Profitability Focus**: The emphasis has shifted from growth to profitability, with strategies to improve operating leverage and drive sales of Xtant branded products [10][19] Additional Important Content - **Distribution Network**: Xtant Medical has a large distribution network with over 450 IDN contracts and 670 independent distributors [4] - **Product Categories**: The company manufactures products across five major orthopedic categories and is expanding into new areas such as surgical repair and chronic wound care [6][18] - **Cash Position**: The company expects to have over $20 million in cash post-sale, alleviating previous concerns about tight cash flow [6][20] - **Future Outlook**: The company anticipates continued growth of 11% to 15% year-over-year, with a strong focus on enhancing product offerings and market penetration [8][21] This summary encapsulates the key insights from the conference call, highlighting the strategic direction and financial health of Xtant Medical Holdings Inc.